Pharmaceutical Technology Europe E-Alert

Pharmaceutical Technology E-Alert: Having trouble viewing this e-mail? Click here.

BLOG

EVENT CALENDAR

COLUMNS

WHITE PAPERS

THE MAGAZINE

20 February 2013

PRINT SUBSCRIBE

IN THIS ISSUE
• News
• Webcasts
• Events
• About Us

Drug Discovery Initiative Launched in Europe
An international consortium of pharmaceutical companies, academia, research organisations, and other related entities have launched a new platform to help enhance drug discovery in Europe. More...

Lilly Discontinues Phase III Rheumatoid Arthritis Program
Eli Lilly and Co. have discontinued its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy. More...

Pharma Companies Fight Healthcare Cost-Containment Policies in Europe
The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight. More...

GSK Announces Fourth Quarter 2012 Results and 2013 Plans
GSK ended 2012 with Group sales down 1%, although sales were flat excluding prior-year comparisons related to over-the-counter product disposals. More...

Biogen Acquires Full Tysabri Rights from Elan
Biogen Idec has agreed to acquire full Tysabri rights from Elan, and will use its existing cash reserves to make a payment of $3.25 billion upon the closing of the transaction, as well as future contingent payments to Elan. More...

Lycera and MSD Collaborate on Autoimmune Therapies
The biopharmaceutical company Lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercializing small-molecule therapies for treating a range of autoimmune diseases. More...

Navigating Emerging Markets — Eastern Europe
The regulatory environment in Europe is evolving, with significant effort to make regulations, including those governing pharmaceuticals and medical devices, more uniform across the region. More...

A Call to Integrate Technology Innovation and Healthcare
In an article called “Beyond magic bullets: true innovation in health care,” scientists from Janssen encouraged the healthcare industry to think outside of the drug product-focused box and look at an integrated approach to care. More...

Product Profiles

Nisso America

Nisso HPC (hydroxypropyl cellulose)
High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application.

Shimadzu

Nexera X2 – X-ceptional insights
Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.

National Institute for Bioprocessing Research and Training (NIBRT)

Advanced biopharmaceutical training in the most cutting-edge analytical methods and techniques: NIBRT's state-of-the-art facility in Dublin, Ireland provides comprehensive, innovative training solutions for academia and industry.